Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats

F Noble, JM Soleilhac, E Soroca-Lucas, S Turcaud, MC Fournie-Zaluski and BP Roques

Department de Chimie Organique, U 266 INSERM, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France.

N-([(R,S)-2-benzyl-3[(S)(2-amino-4-methylthio)butyl dithio]-1- oxopropyl)-L-phenylalanine benzyl ester (RB101) is the first systemically active prodrug generating through a biologically dependent cleavage of the disulfide bond the potent (S)2-amino-1-mercapto-4- methylthio butane (aminopeptidase N) (IC50 = 11 nM) and N-[(R,S)-2- mercapto-methyl-1-oxo-3-phenylpropyl]-L-phenylalanine (neutral endopeptidase) (IC50 = 2 nM) inhibitors (aminopeptidase N). RB101 easily crosses the blood-brain barrier, as shown by the observed complete inhibition of cerebral endopeptidase 24.11 after i.v. injection in mice. The prodrug induces strong, dose-dependent antinociceptive responses in mice after i.v., i.p. or s.c. administration, in the hot plate (ED50 = 9 mg/kg) and phenylbenzoquinone-induced writhing (ED50-3.25 mg/kg) tests in mice, which are currently used in analgesics screening. RB101 is also active in the tail-flick and tail-electric stimulation tests in rats. In contrast, under disulfide forms, the above selective aminopeptidase N or endopeptidase 24.11 inhibitors are inactive after i.v. administration and their association 3 times less potent than RB101 alone. In all the tests used, the pain-alleviating effect of RB101 was suppressed by naloxone, but, except for the tail-flick and the motor response to tail-electric stimulation, not by the delta-selective antagonist naltrindole. The preferential involvement of mu opioid receptors in the analgesic effects of endogenous enkephalins, whose extracellular levels are increased by the two RB101-generated inhibitors, is suggested by the similar apparent pA2 values for RB101- naloxone (pA2: 7.53 +/- 0.046) and DAMGO (mu-selective ligand)-naloxone (pA2: 7.38 +/- 0.049).(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 261, Issue 1, pp. 181-190, 04/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				E. M. Jutkiewicz The Antidepressant -like Effects of Delta-Opioid Receptor Agonists Mol. Interv., June 1, 2006; 6(3): 162 - 169. [Abstract] [Full Text] [PDF]

				B. Song and J. C. G. Marvizon Peptidases Prevent {micro}-Opioid Receptor Internalization in Dorsal Horn Neurons by Endogenously Released Opioids J. Neurosci., March 1, 2003; 23(5): 1847 - 1858. [Abstract] [Full Text] [PDF]

				H. Chen, F. Noble, P. Coric, M.-C. Fournie-Zaluski, and B. P. Roques Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: A class of central analgesics PNAS, September 29, 1998; 95(20): 12028 - 12033. [Abstract] [Full Text] [PDF]

				P. Honoré, J. Buritova, M.-C. Fournié-Zaluski, B. P. Roques, and J.-M. Besson Antinociceptive Effects of RB101, a Complete Inhibitor of Enkephalin-catabolizing Enzymes, Are Enhanced by a Cholecystokinin Type B Receptor Antagonist, as Revealed by Noxiously Evoked Spinal c-Fos Expression in Rats J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 208 - 217. [Abstract] [Full Text]